In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum.
autonomic nervous system dysfunction
energy homoeostasis
glucose homeostasis
glucose metabolism
glycated hemoglobin (HbA1c)
homeostasis
pressure pain sensitivity
type 2 diabetes
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
10
2022
accepted:
18
04
2023
medline:
30
6
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
The autonomic nervous system (ANS) maintains glucose homeostasis. While higher than normal glucose levels stimulate the ANS toward reduction, previous findings suggest an association between sensitivity to, or pain from, pressure at the chest bone (pressure or pain sensitivity, PPS) and activity of the ANS. A recent randomized controlled trial (RCT) of type 2 diabetes (T2DM) suggested that addition of an experimental, non-pharmacological intervention more effectively than conventional treatment lowered the levels of both PPS and HbA1c. We tested the null hypothesis that conventional treatment ( In the conventional group, PPS reverters experienced normalization of HbA1c that corrected the basal increase, thus disproving the null hypothesis. With the addition of the experimental program, PPS reverters experienced similar reduction. The reduction of HbA1c among reverters averaged 0.62 mmol/mol per mmol/mol increase of baseline HbA1c ( In consecutive analyses of two different populations of individuals with T2DM, we demonstrated that the higher the baseline HbA1c, the greater the reduction of HbA1c but only in individuals with a concomitant reduction of sensitivity to PPS, suggesting a homeostatic effect of the autonomic nervous system on glucose metabolism. As such, ANS function, measured as PPS, is an objective measure of HbA1c homeostasis. This observation may be of great clinical importance.
Sections du résumé
Background
UNASSIGNED
The autonomic nervous system (ANS) maintains glucose homeostasis. While higher than normal glucose levels stimulate the ANS toward reduction, previous findings suggest an association between sensitivity to, or pain from, pressure at the chest bone (pressure or pain sensitivity, PPS) and activity of the ANS. A recent randomized controlled trial (RCT) of type 2 diabetes (T2DM) suggested that addition of an experimental, non-pharmacological intervention more effectively than conventional treatment lowered the levels of both PPS and HbA1c.
Materials and analyses
UNASSIGNED
We tested the null hypothesis that conventional treatment (
Results
UNASSIGNED
In the conventional group, PPS reverters experienced normalization of HbA1c that corrected the basal increase, thus disproving the null hypothesis. With the addition of the experimental program, PPS reverters experienced similar reduction. The reduction of HbA1c among reverters averaged 0.62 mmol/mol per mmol/mol increase of baseline HbA1c (
Conclusion
UNASSIGNED
In consecutive analyses of two different populations of individuals with T2DM, we demonstrated that the higher the baseline HbA1c, the greater the reduction of HbA1c but only in individuals with a concomitant reduction of sensitivity to PPS, suggesting a homeostatic effect of the autonomic nervous system on glucose metabolism. As such, ANS function, measured as PPS, is an objective measure of HbA1c homeostasis. This observation may be of great clinical importance.
Identifiants
pubmed: 37389368
doi: 10.3389/fnins.2023.1067098
pmc: PMC10303981
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1067098Informations de copyright
Copyright © 2023 Faber, Ballegaard, Ørsted, Eldrup, Karpatschof, Gyntelberg, Hecquet and Gjedde.
Déclaration de conflit d'intérêts
SB is a shareholder in the company that holds the patent for the PPS measurement device. He did not participate in participant selection, examinations, or evaluation of the examinations. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neuropharmacology. 2019 Aug;154:34-49
pubmed: 30503993
Diabet Med. 2022 Jan;39(1):e14688
pubmed: 34519086
Front Physiol. 2019 Apr 26;10:457
pubmed: 31133864
Scand J Clin Lab Invest. 2014 Mar;74(2):116-25
pubmed: 24313546
Diabetes Metab J. 2019 Feb;43(1):3-30
pubmed: 30793549
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13256-60
pubmed: 16916936
J Epidemiol. 2015;25(9):583-91
pubmed: 26277879
Scand J Clin Lab Invest. 2013 Aug;73(5):373-9
pubmed: 23607612
Crit Rev Clin Lab Sci. 2015;52(4):180-90
pubmed: 26042993
Am J Physiol Regul Integr Comp Physiol. 2019 Apr 1;316(4):R301-R317
pubmed: 30649893
Front Neurosci. 2021 Mar 11;15:613858
pubmed: 33776633
J Pain. 2009 Jun;10(6):556-72
pubmed: 19380256
Brain Stimul. 2015 Jul-Aug;8(4):702-7
pubmed: 25758422
Diabetes. 2013 Dec;62(12):3976-86
pubmed: 24264395
Acupunct Electrother Res. 1993 Apr-Jun;18(2):103-15
pubmed: 7902640
Bioelectron Med. 2018 Jul 4;4:9
pubmed: 32232085
Dis Colon Rectum. 2011 Mar;54(3):318-23
pubmed: 21304303
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042373
Endocr J. 2012;59(5):365-74
pubmed: 22293586
Diabetes Care. 2010 Oct;33(10):2285-93
pubmed: 20876709
Sci Adv. 2019 Jun 19;5(6):eaav9946
pubmed: 31223654
Diabetes Metab Res Rev. 2020 Mar;36(3):e3229
pubmed: 31655012
Front Psychol. 2015 Jan 12;5:1529
pubmed: 25628581
CMAJ. 2017 Mar 6;189(9):E341-E364
pubmed: 27799615
BMJ Open Diabetes Res Care. 2020 Jun;8(1):
pubmed: 32518063